✦ LIBER ✦

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

✍ Scribed by Francisco J Esteva, Carol D Cheli, Herbert Fritsche…

Book ID: 120699916
Publisher: BioMed Central
Year: 2005
Tongue: English
Weight: 195 KB
Volume: 7
Category: Article
ISSN: 1465-5411
DOI: 10.1186/bcr1020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum HER-2/neu and relative resistance

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

✍ Suhail M. Ali; Walter P. Carney; Francisco J. Esteva; Monica Fornier; Lyndsay Ha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 2 views

The level of HER2/neu gene amplification

The level of HER2/neu gene amplification as predictive factor in patients with metastatic breast cancer treated with a trastuzumab-based therapy

✍ G. Gullo; D. Bettio; V. Torri; G. Masci; P. Salvini; A. Santoro 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

KI67 and p53 are not predictive of tumor

KI67 and p53 are not predictive of tumor response or survival with trastuzumab-based therapy in metastatic breast cancer patients (pts) with her2/neu-overexpression

✍ A. Schneeweiss; F. Lenz; F. Beldermann; M. Geberth; R. Goerner; P. Sinn; H.-J. S 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 171 KB

Elevation of the serum HER2/neu level is

Elevation of the serum HER2/neu level is associated with shorter progression-free survival after chemotherapy in metastatic breast cancer

✍ D. Lueftner; C. Akrivakis; P. Henschke; B. Flath; R. Geppert; K. Wernecke; K. Po 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 372 KB

Differential survival following trastuzu

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

✍ Masakazu Toi; Jeff Sperinde; Weidong Huang; Shigehira Saji; John Winslow; Xuegua 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 393 KB